Blog Archive
-
▼
2008
(233)
-
▼
July
(23)
- MicroIslet : Safety and Efficacy Data Update
- CombinatoRx : Progress in Key Programs at 2008 R&D...
- Metabolon : Collaboration with the University of T...
- Santarus and Depomed : U.S. Promotion Agreement fo...
- International Stem Cell and Novocell : Collaborati...
- XOMA 052 Phase 1 Data to be Presented At European ...
- Hollis Eden Pharmaceuticals : Phase II Clinical Tr...
- Genaera : Data on Mechanism of Inhibition of PTP-1...
- Emisphere Technologies : Data From Independent Cli...
- Animas Corporation : OneTouch Ping Glucose Manage...
- Echo Therapeutics : Clinical Study of Its Symphony...
- BodyTel : to Launch GlucoTel System in August
- Axis-Shield : AFINION HbA1c patent granted in USA
- AgaMatrix : New WaveSense Presto and Pro Glucose M...
- ARKRAY USA : National Launch of GLUCOCARD X-METER
- Georgetown University Teams with Gentag and SAIC :...
- Emisphere : License Agreement With Novo Nordisk to...
- Debiotech and STMicroelectronics : First Prototype...
- Abbott : Phase III Sub-Group Analysis Shows Invest...
- ProStrakan : Novel Testosterone Gel Significantly ...
- Isis : Robust Drug Portfolio for Diabetes and Obes...
- Sangamo BioSciences : Presentation of Phase 1b ZFP...
- HemoCue : First FDA CLIA Waiver in Diagnostics Ind...
-
▼
July
(23)
Thursday, July 10, 2008
Animas Corporation : OneTouch Ping Glucose Management System Cleared by FDA
July 1, 2008 – Animas Corporation announced the clearance of its OneTouch® Ping™ Glucose Management System by the U.S. Food and Drug Administration (FDA). OneTouch Ping is the first full-feature insulin pump that wirelessly communicates with a blood glucose meter-remote. Using the OneTouch Ping meter-remote, a person can calculate insulin doses and opt to wirelessly instruct the pump to deliver them without touching the pump at all, giving patients more freedom and flexibility in using their insulin pump... Animas Corporation's Press Release -
Libellés :
Animas,
Blood Glucose Monitoring,
Insulin